RPRosa Parisi

Rosa Parisi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rosa Parisi has a total of 120 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Work impact of immune‐mediated inflammatory skin diseases: A systematic review and meta‐analysis

    by Fanny C. Kpenou, Ju Hee Han, Marc Fadel, Tat‐Thang Vo, Hyun Jeong Ju, Tarik El Aarbaoui, Christopher E. M. Griffiths, Henry W. Lim, Lars E. French, Carsten Flohr, et al.

    Background: Patients with immune‐mediated inflammatory diseases (IMIDs) of the skin face challenges beyond visible signs. Despite their significant psychosocial burden, the global impact of skin IMIDs on work productivity has not been systematically reviewed. Objective: To evaluate the global burden of skin IMIDs on work productivity. Methods: We conducted a systematic review and meta‐analysis. Eight electronic databases (PubMed, Web of Science Core Collection, Embase, SciELO, KCI Korean Journal Database, Global Index Medicus, Informit and Google Scholar) were searched from inception to June 2024. We included quantitative studies reporting work‐related outcomes in adults (≥18 years) with alopecia areata, atopic dermatitis, hidradenitis suppurativa, psoriasis or vitiligo. For the meta‐analysis, studies had to report Work Productivity and Activity Impairment (WPAI), Work Limitations Questionnaire (WLQ) or sick leave duration. Two reviewers independently screened and extracted data. Risk of bias was assessed using validated tools. Data were pooled using frequentist and Bayesian approaches to ensure estimations robustness across heterogeneous designs and sample sizes. Results: Across 100 studies with a cumulative sample of 306,619 participants worldwide, skin IMIDs were consistently associated with impaired work functioning. Notably, the mean WPAI overall work impairment was 28.96 (95% CI 25.61; 32.31), and participants averaged 16.74 days of sick leave per year (95% CI 7.39; 26.1). Findings suggest that occupational impairment was influenced by psychosocial factors, thereby highlighting broader societal and economic consequences. Conclusion: Skin IMIDs substantially reduce work functioning and productivity worldwide, representing an underrecognized burden on individuals, employers and health systems. Better multidisciplinary strategies are needed to prevent occupational disadvantage and mitigate the economic and social impact of these chronic conditions.

  • Open Access

    Mapping the global work-related impact of immune-mediated inflammatory skin diseases: A systematic review

    by Fanny C. Kpenou, Ju Hee Han, Marc Fadel, Tat-Thang Vo, Hyun Jeong Ju, Tarik El Aarbaoui, Christopher E.M. Griffiths, Henry W. Lim, Lars E. French, Carsten Flohr, et al.

  • Open Access

    Psoriasis and risk of 26 cancers: pooled population-based cohort studies from Denmark, England, Israel and Taiwan

    by Alex M Trafford, Yochai Schonmann, Teng-Chou Chen, Alexander Egeberg, Rosa Parisi, Evangelos Kontopantelis, Ting-Chun Wang, Martin K Rutter, Li-Chia Chen, Tjeerd van Staa, et al.

    Background: Psoriasis is a chronic inflammatory skin disease, and the risk of developing cancer has been postulated due to the presence of several plausible underlying mechanisms. Understanding the association between psoriasis and cancer is imperative to the provision of optimal psoriasis care. Objectives: To examine the risk of developing cancer in individuals with psoriasis. Methods: Population-based cohort studies were conducted in Denmark, England, Israel and Taiwan through the use of linked electronic health records. Individuals aged at least 18 years with a diagnosis of psoriasis in the country-specific study period were matched with up to six comparators with no record of psoriasis prior to the index date. Country-specific hazard ratios for the risk of cancer development overall and for 26 site-specific cancers between individuals with and without psoriasis were calculated through Cox regression. Country-specific estimates were pooled using random effects modelling. Results: We included 702 022 individuals with psoriasis and 4 185 342 matched comparators. In models implicitly controlled for age, sex and calendar time by matching, there was a small association between psoriasis and cancer overall [pooled HR (pHR) 1.08, 95% confidence interval (CI) 1.04–1.13; I2 = 92.4%]. Adjustment for potential confounding factors resulted in a slight attenuation of risk (pHR 1.05, 95% CI 1.01–1.09; I2 = 81.2%). When restricted to those with moderate-to-severe psoriasis, the risk of cancer overall was slightly higher (pHR 1.16, 95% CI 1.04–1.28; I2 = 92.8%) than in confounder-adjusted models (pHR 1.09, 95% CI 1.03–1.15; I2 = 60.6%). Associations with psoriasis were present for oral cavity (pHR 1.29, 95% CI 1.12–1.47; I2 = 55.4%), pharynx (pHR 1.30, 95% CI 1.07–1.58; I2 = 58.4%), oesophagus (pHR 1.17, 95% CI 1.03–1.33; I2 = 56.6%), liver (pHR 1.53, 95% CI 1.33–1.77; I2 = 75.1%), pancreas (pHR 1.09, 95% CI 1.02–1.17; I2 = 0.0%), kidney (pHR 1.19, 95% CI 1.11–1.27; I2 = 0.0%), bladder (pHR 1.13, 95% CI 1.06–1.20; I2 = 28.7%) and keratinocyte cancers (pHR 1.37, 95% CI 1.16–1.63; I2 = 97.5%), and Hodgkin lymphoma (pHR 1.56, 95% CI 1.16–2.11; I2 = 69.7%), non-Hodgkin lymphoma (pHR 1.16, 95% CI 1.07–1.26; I2 = 35.5%) and leukaemia (pHR 1.18, 95% CI 1.08–1.29; I2 = 41.9%). Site-specific associations generally persisted, with slight risk exacerbations and additional associations for lung and ovarian cancers, when limited to people with moderate-to-severe psoriasis. Conclusions: Psoriasis was associated with an increased risk of developing 14 of 26 investigated site-specific cancers, including cancers with a poor prognosis, such as liver, lung and oesophageal cancer. Our findings can be used to reinforce cancer prevention strategies in psoriasis care.


  • Open Access

    Development and evaluation of an online training tool to aid in the diagnosis of chronic plaque psoriasis

    by Maha Abo‐Tabik, Rosa Parisi, Mark Hann, Rod Tucker, Sarah Willis, Darren M. Ashcroft, Christopher E. M. Griffiths, the Global Psoriasis Atlas (GPA)

    Background: Chronic plaque psoriasis (CPP) is underdiagnosed, undertreated and mistaken for other skin conditions such as eczema, tinea corporis and pityriasis rosea.Objectives: To develop and evaluate an online training tool to improve the diagnostic skills of nondermatologists for CPP.Methods: The study involved: (i) developing an online training tool to improve CPP diagnosis by nondermatologists; and (ii) evaluating the performance of the newly developed training tool by conducting a before‐and‐after exploratory investigation. Participants included three groups of primary care health professionals: general practitioners (GPs); nurses; and pharmacists. The tool contained written recommendations for the diagnosis of CPP in different skin colours and a medical artist's illustrations of psoriasis to overcome the lack of representative images of the disease in skin of colour and to illustrate the salient features more clearly than clinical photographs.Results: In total, 60 participants completed the study (20 per participant group). The training tool improved participants' diagnostic skills for CPP. The diagnostic ability of GPs was, on average, higher than nurses and pharmacists before and after training. Participants found the training valuable and relevant to CPP diagnosis in primary care settings.Conclusions: Our findings show that a training tool, using medical illustrations, for nondermatologists can be beneficial in terms of recognition of CPP. This may lead to more timely diagnosis and treatment of psoriasis and support relevant and faster referral to specialist dermatology clinics.


  • Open Access

    GP working time and supply, and patient demand in England in 2015–2022: a retrospective study

    by Rosa Parisi, Yiu-Shing Lau, Peter Bower, Katherine Checkland, Jill Rubery, Matthew Sutton, Sally Giles, Aneez Esmail, Sharon Spooner, Evangelos Kontopantelis

    Background: English primary care faces a reduction in GP supply and increased demand.Aim: To explore trends in GP working time and supply, accounting for factors influencing demand for services.Design and setting: Retrospective observational study in English primary care between 2015 and 2022.Method: Trends in median GP contracted time commitment were calculated using annual workforce datasets. Three measures of demand were calculated at practice-level: numbers of patients; numbers of older patients (≥65 years); and numbers of chronic conditions using 21 Quality and Outcomes Framework disease registers. Multi-level Poisson models were used to assess associations between GP supply and practice demand, adjusted for deprivation, region, and year.Results: Between 2015 and 2022, the median full-time equivalent (FTE) of a fully qualified GP decreased from 0.80 to 0.69.There was a 9% increase in registered population per GP FTE (incidence rate ratio [IRR] = 1.09; 95% confidence interval [CI] = 1.05 to 1.14). This increase was steeper using numbers of chronic conditions (32%, IRR = 1.32; 95% CI = 1.26 to 1.38). Practices in the most deprived decile had 17% more patients (IRR = 1.17; 95% CI = 1.08 to 1.27) and 19% more chronic conditions (IRR = 1.19; 95% CI = 1.06 to 1.33) per GP FTE, compared with the least deprived decile. These disparities persisted over time. All regions reported more chronic conditions per GP FTE than London.Conclusion: Population demand per GP has increased, particularly in terms of chronic conditions. This increase is driven by several factors, including a reduction in GP contracted time commitments. Persistent deprivation gradients in GP supply highlight the need to recruit and retain GPs more equitably.


  • Open Access

    Performance of CHA2DS2-VASc and HAS-BLED in predicting stroke and bleeding in atrial fibrillation and cancer

    by Alyaa M Ajabnoor, Salwa S Zghebi, Rosa Parisi, Darren M Ashcroft, Corinne Faivre-Finn, Mamas A Mamas, Evangelos Kontopantelis

    To compare the predictive performance of CHA2DS2-VASc and HAS-BLED scores in atrial fibrillation (AF) patients with and without cancer. Using data from the Clinical Practice Research Datalink in England, we performed a retrospective cohort study of patients with new diagnoses of AF from 2009 to 2019. Cancer was defined as history of breast, prostate, colorectal, lung, or haematological cancer. We calculated the CHA2DS2-VASc and HAS-BLED scores for the 1-year risk of stroke and major bleeding events. Scores performance was estimated by discrimination [area under the receiver operating characteristic curve (AUC)] and calibration plots. Of 141 796 patients with AF, 10.3% had cancer. The CHA2DS2-VASc score had good to modest discrimination in prostate cancer AUC = 0.74 (95% confidence interval: 0.71, 0.77), haematological cancer AUC = 0.71 (0.66, 0.76), colorectal cancer AUC = 0.70 (0.66, 0.75), breast cancer AUC = 0.70 (0.66, 0.74), and lung cancer AUC = 0.69 (0.60, 0.79), compared with no-cancer AUC = 0.73 (0.72, 0.74). HAS-BLED discrimination was poor in prostate cancer AUC = 0.58 (0.55, 0.61), haematological cancer AUC = 0.59 (0.55, 0.64), colorectal cancer AUC = 0.57 (0.53, 0.61), breast cancer AUC = 0.56 (0.52, 0.61), and lung cancer AUC = 0.59 (0.51, 0.67), compared with no-cancer AUC = 0.61 (0.60, 0.62). Both the CHA2DS2-VASc score and HAS-BLED score were well calibrated across all study cohorts. Amongst certain cancer cohorts in the AF population, CHA2DS2-VASc performs similarly in predicting stroke to AF patients without cancer. Our findings highlight the importance of cancer diagnosis during the development of risk scores and opportunities to optimize the HAS-BLED risk score to better serve cancer patients with AF.


  • Open Access

    Trends in full-time working in general practice: a repeated cross-sectional study

    by Joseph Hutchinson, Jon Gibson, Evangelos Kontopantelis, Kath Checkland, Sharon Spooner, Rosa Parisi, Matt Sutton

    Background: There is little evidence and no agreement on what constitutes full-time working for GPs. This is essential for workforce planning, resource allocation, and accurately describing GP activity.Aim: To clarify the definition of full-time working for GPs, how this has changed over time, and whether these changes are explained by GP demographics.Design and setting: Data were obtained from repeated cross-sectional national surveys for GPs, which were conducted between 2010 and 2021.Method: A comparison was undertaken of three measures of working time commitments (hours and sessions per week and hours per session) plus a measure of workload intensity across survey years. Multiple regression was used to adjust the changes over time for age, sex, ethnicity, contract type, area deprivation, and rurality. Unadjusted hours and sessions per week were compared with definitions of full-time working.Results: Average hours and sessions per week reduced from 40.5 (95% confidence interval [CI] = 38.5 to 42.5) to 38.0 (95% CI = 36.3 to 39.6) and 7.3 (95% CI = 7.2 to 7.3) to 6.2 (95% CI = 6.2 to 6.3) between 2010 and 2021, respectively. In 2021, 54.6% of GPs worked at least 37.5 hours per week and 9.5% worked at least nine sessions. Hours per session increased from 5.7 (95% CI = 5.7 to 5.7) to 6.2 (95% CI = 6.2 to 6.3) between 2010 and 2021. Partners worked more hours, sessions, and hours per session. Adjustments expanded the increase in hours per session from 0.54 to 0.61.Conclusion: At the current average duration of sessions, six sessions per week aligns with the NHS definition of full-time hours. However, hours per week is a more consistent way to define full-time work for GPs.


  • Open Access

    Common Cancer Types and Risk of Stroke and Bleeding in Patients With Nonvalvular Atrial Fibrillation: A Population‐Based Study in England

    by Alyaa M. Ajabnoor, Rosa Parisi, Salwa S. Zghebi, Darren M. Ashcroft, Corinne Faivre‐Finn, Charlotte Morris, Mamas A. Mamas, Evangelos Kontopantelis

    Background: The association between cancer and stroke or bleeding outcomes in atrial fibrillation is unclear. We sought to examine how certain types of cancer influence the balance between stroke and bleeding risk in patients with nonvalvular atrial fibrillation (NVAF). Methods and Results: We estimated stroke and bleeding risk among adult patients with NVAF and certain types of cancer (breast, prostate, colorectal, lung, and hematological cancer) from 2009 to 2019 based on data from the UK Clinical Practice Research Datalink GOLD and Aurum databases. The control group included patients with NVAF only. Of 177 065 patients with NVAF, 11379 (6.4%) had cancer (1691 breast, 3955 prostate, 1666 colorectal, 2491 hematological, and 1576 lung). Compared with patients without cancer, stroke risk was higher in patients with breast cancer (adjusted hazard ratio [aHR], 1.20 [95% CI, 1.07–1.35) and with prostate cancer (aHR, 1.11 [95% CI, 1.01–1.12) if diagnosed within 6 months before NVAF. The risk of bleeding was increased in subjects with hematological cancer (aHR, 1.55 [95% CI, 1.40–1.71]), lung cancer (aHR, 1.49 [95% CI, 1.25, 1.77]), prostate cancer (aHR, 1.38 [95% CI, 1.28–1.49]), and colorectal cancer (aHR, 1.36 [95% CI, 1.21–1.53]), but not for subjects with breast cancer. The more recent the cancer diagnosis before NVAF diagnosis (within 6 months), the higher the risk of bleeding. Conclusions: Breast and prostate cancer are associated with increased stroke risk, whereas in some cancer types, the risk of bleeding seemed to exceed stroke risk. In these patients, prescribing of oral anticoagulant should be carefully evaluated to balance bleeding and stroke risk.


  • Open Access

    Predictors and population health outcomes of persistent high GP turnover in English general practices: a retrospective observational study

    by Rosa Parisi, Yiu-Shing Lau, Peter Bower, Katherine Checkland, Jill Rubery, Matt Sutton, Sally J Giles, Aneez Esmail, Sharon Spooner, Evangelos Kontopantelis

    Objective English primary care faces significant challenges, including ‘persistent high turnover’ of general practitioners (GPs) in some partnerships. It is unknown whether there are specific predictors of persistent high turnover and whether it is associated with poorer population health outcomes. Design A retrospective observational study. Methods We linked workforce data on individual GPs to practice-level data from Hospital Episode Statistics and the GP Patient Survey (2007–2019). We classified practices as experiencing persistent high turnover if more than 10% of GPs changed in at least 3 consecutive years. We used multivariable logistic or linear regression models for panel data with random effects to identify practice characteristics that predicted persistent high turnover and associations of practice outcomes (higher emergency hospital use and patient experience of continuity of care, access to care and overall patient satisfaction) with persistent high turnover. Results Each year, 6% of English practices experienced persistent high turnover, with a maximum of 9% (688/7619) in 2014. Larger practices, in more deprived areas and with a higher morbidity burden were more likely to experience persistent high turnover. Persistent high turnover was associated with 1.8 (95% CI 1.5 to 2.1) more emergency hospital attendances per 100 patients, 0.1 (95% CI 0.1 to 0.2) more admissions per 100 patients, 5.2% (95% CI −5.6% to −4.9%) fewer people seeing their preferred doctor, 10.6% (95% CI−11.4% to −9.8%) fewer people reporting obtaining an appointment on the same day and 1.3% (95% CI −1.6% to −1.1%) lower overall satisfaction with the practice. Conclusions Persistent high turnover is independently linked to indicators of poorer service and health outcomes. Although causality needs to be further investigated, strategies and policies may be needed to both reduce high turnover and support practices facing challenges with high GP turnover when it occurs.


  • Open Access

    Mapping opportunities for the earlier diagnosis of psoriasis in primary care settings in the UK: results from two matched case–control studies

    by Maha Abo-Tabik, Rosa Parisi, Catharine Morgan, Sarah Willis, Christopher Em Griffiths, Darren M Ashcroft

    Background: The diagnosis of psoriasis may be missed or delayed in primary care settings.Aim: To examine trends in healthcare events before a diagnosis of psoriasis.Design and setting: Two matched case–control studies using electronic healthcare records delineated from the Clinical Practice Research Datalink (CPRD GOLD and Aurum) in the UK.Method: Individuals aged ≥18 years with an incident diagnosis of psoriasis (case group) between 1 January 2010 and 29 December 2017 were identified and matched by age, sex, and general practice with six individuals without psoriasis (control group). Healthcare activities were examined and annual incidence rates and incidence rate ratios (IRRs) with 95% confidence intervals (CIs) for 10 years before the index date were compared between case and control groups.Results: There were 17 320 people with psoriasis and 99 320 controls included from CPRD GOLD, and 11 442 people with psoriasis and 65 840 controls extracted from CPRD Aurum. Data from CPRD GOLD showed that people with psoriasis were up to eight times more likely to be diagnosed with pityriasis rosea at 6 months (IRR 7.82, 95% CI = 4.09 to 14.95) before the index date than the control group. The case group were twice as likely to be diagnosed with eczema (IRR 1.90, 95% CI = 1.76 to 2.05) or tinea corporis (IRR 1.99, 95% CI = 1.74 to 2.27) 1 year before the index date. The case group were more likely to report dry skin, rash, skin texture changes, and itching than the control group up to 5 years before the index date. The most frequently reported clinical feature was rash with an IRR of 2.71 (95% CI = 2.53 to 2.92) at 1 year before the index date. The case group were prescribed topical corticosteroids (IRR 1.97, 95% CI = 1.88 to 2.07) or topical antifungals (IRR 1.92, 95% CI = 1.78 to 2.07) in the year before the index date twice as often as those in the control group.Conclusion: Findings suggest that the diagnosis of psoriasis may be missed or delayed in a UK primary care setting for up to 5 years for some individuals, hence leading to a potentially detrimental delay in establishing an appropriate treatment regimen.